AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
from BUSINESS LINE, May 31, 2009 Mumbai, May 30 - Drug maker Sun Pharmaceutical took a 46 per cent hit on its export in the last quarter of the financial year ended March 31, 2009, impacting its consolidated bottomline for the same period.
"Performance in the fourth quarter in the US has been below expectations, partly on account of product recalls initiated by Caraco, though the recurring business growth remains encouraging," said Sun Pharma's Chairman and Managing Director, Mr Dilip Shanghvi, in a statement from the company.
However, he added, the company continued to receive product approvals in the US from all its other facilities.
"We remain focused on …